M-LIFE™ ANNOUNCES PRESIDENT OF M-TUBULIN™ SUBSIDIARY
12 Sep 2023
Executive Change
-Advancing new prospective cancer drugs with the philosophy of enabling patients to live better for longer rather than longer for worse
NASHVILLE, TENNESSEE, September 6, 2023 – M-LIFE™ today announced that Eric Rubenstein, MD has been named as new President of its M-Tubulin subsidiary. Ted Moskal, M-Life™ CEO said, “we are delighted that Doctor Rubenstein is taking the reins of M-Tubulin as its new president. Doctor Rubenstein is an experienced board-certified oncologist and practicing clinician. He brings a wealth of experience in oncology therapeutics as well as clinical trials.”
“I am very excited to be joining the M-Tubulin Team,” said Rubenstein. “I believe M-Tubulin has both an innovative business strategy and talented management team that is uniquely positioned to capitalize on the changing therapeutics environment. As drug discovery continues to gravitate towards AI machine based learning technologies, I believe M-Tubulin is in a position to offer the first class of prospective drugs designed in silico, prioritizing the patient experience. Our goal is to avail new cancer drugs for malignancies where there are few or no effective treatment options. And we believe that our botanically derived approach will allow patients to live longer and better lives as a result of our emphasis on maximizing effect while reducing drug toxicity.”
Dr. Rubenstein formerly served as the Director of Medical Oncology at the MedStar Georgetown Cancer Institute in Clinton MD; as well as Medical Director of Oncology Research (2012-2018) at Franciscan Health in Indianapolis; where he oversaw all clinical trials and helped build an internationally recognized cardio-oncology program. He has been a physician investigator and enrolled patients on clinical trials for a multitude of solid and liquid tumors at a tertiary referral center servicing much of rural Indiana. While working with MedStar he helped support the Georgetown Lombardi Center and MedStar Washington Hospital Center working with disease groups to ensure Southern Maryland neuro-oncology and leukemia patients could receive treatments close to home.
Dr. Rubenstein is a recognized proponent of advanced therapeutic treatments with enrollment of patient in both Cooperative group and Industry sponsored clinical trials for a myriad of novel oncolytic agents. He is an advocate for delivering equitable value-based care; prioritizing and expanding access to clinical research. He is a former board member of the Indianapolis Leukemia and Lymphoma Society. Dr. Rubenstein has been focused on bridging the gap between clinical trials and real-world data (RWD). Currently Dr. Rubenstein is a founding member of Cancer X, a public private partnership announced by the White House as a national accelerator to boost innovation in the fight against cancer.
About M-Life™
M-Life™ is a life sciences, molecule discovery company focusing on the development of new drugs, agricultural and diagnostics related chemicals. Whether a new antibiotic, non-opiate analgesic or environmentally friendly herbicide, the Company aims to address gaps in the present life sciences markets making life better. To learn more about M-Life™, please visit us at
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.